A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting productsforhemorrhoid to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.

Antihistamines As the name indicates, an antihistamine counters the effects of histamine, which is released by the mast cells in the body''s tissues and contributes productsforhemorrhoid to allergy symptoms. For many years, antihistamines productsforhemorrhoid have proven productsforhemorrhoid useful in relieving sneezing and itching in the nose, throat, productsforhemorrhoid and eyes and in reducing nasal swelling and drainage. Many people who take antihistamines experience some distressing side effects: drowsiness productsforhemorrhoid and loss of alertness and coordination. In children, such reactions can be misinterpreted as behavior problems. During the last few years, however, antihistamines productsforhemorrhoid that cause fewer of these side effects have become available by prescription. These new nonsedating antihistamines are as effective as other antihistamines in preventing histamine-induced symptoms, but do so without causing sleepiness.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. productsforhemorrhoid In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed productsforhemorrhoid by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6